Publications

Back to Publications

Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

J Am Heart Assoc 2022;11:e025045 DOI: 10.1161/JAHA.121.025045

This secondary analysis of the CREDENCE trial showed that canagliflozin reduced cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total than first cardiovascular events.


LinkedIn